Dynamic expression of bFGF and TGFβ2 in glomus cell grafts of carotid body in rat model of parkinson disease

Abstract

To investigate the changes in the expression of basic fibroblast growth factor (bFGF) and transforming growth factor beta 2 (TGF32) in glomus cell grafts of carotid body in the rat model of 6-hydroxydopamine-induced Parkinson disease, immunohistochemical staining of bFGF and TGFβ2 in the sections of striate body was done on the 2nd, 4th and 12th week after transplantation. The results showed that on the 2nd week after transplantation, bFGF annd TGFβ2 were not detectable in the glumous cell grafts. On the 4th week after graft, bFGF and TGFβ2 immunoreactivity was increased within the grafts and at the graft-host interface but was restricted only to astrocytes. In the striatum surrounding the graft, bFGF was expressed persistently, while TGFβ2 showed transient expression. It was suggested that the transient expression of TGFβ2 was likely due more to the trauma imposed by the graft procedure than to an intrinsic. The deficiency in astrocytic bFGF early after graft may be responsible for the poor survival of grafted glomus cells of carotid body.

Keywords

basic fibroblast growth factor / transforming growth factor beta 2 / graft / glomus cell / carotid body

References

[1] RosenthalA. Autotransplants for Parkinson’s disease. Neuron, 1998, 20(2): 169-169

[2] SiegelG J, ChauhanN B. Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain. Brain Res Brain Res Rev, 2000, 33(2–3): 199-199

[3] EspejoE F, MontoroR J, ArmengolJ A, et al.. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. J Neurol, 1998, 20(2): 197-197

[4] HansenJ T, BingG Y, NotterM F, et al.. Paraneuronal grafts in unilateral 6-hydroxydopamine-lesioned rats: morphological aspects of adrenal chromaffin and carotid body glomus cell implants. Prog Brain Res, 1988, 78: 507-507

[5] TornqvistN, BjorklundL, AlmqvistP, et al.. Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson’s disease. Exp Neurol, 2000, 164(1): 130-130

[6] ShultsC W, RayJ, TsuboiK, et al.. Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine. Brain Res, 2000, 883(2): 192-192

[7] KrieglsteinK, Suter-CrazzolaraC, FisherW H, et al.. TGF-β superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+toxicity. EMBO J, 1995, 14: 736-736

[8] SommerC, SabelM, OertelW H, et al.. Temporo-spatial expression of bFGF and TGF beta 2 in embryonic dopaminergic grafts in a rat model of Parkinson’s disease. Brain Res Mol Brain Res, 1999, 69(1): 53-53

[9] MayerE, DunnettS B, PellitteriR, et al.. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons: I. Effects in vitro. Neuroscience, 1993, 56: 379-379

[10] KaneC J M, BrownG J, PhelanK D, et al.. Transforming growth factor β2 stimulates and inhibits neurogenesis of rat cerebellar granule cells in culture. Dev Brain Res, 1996, 96: 46-46